Meeting
2017 ASCO Annual Meeting
Trastuzumab-related subclinical cardiotoxicity in patients with early stage HER2-positive breast cancer: A retrospective single-center cohort study.
Authors
Olexiy Aseyev
Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON, Canada
Olexiy Aseyev , Moira Rushton-Marovac , Freya L. Crawley , Christopher Johnson , Susan Faye Dent
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 35, 2017 (suppl; abstr 10123)
DOI
10.1200/JCO.2017.35.15_suppl.10123
Abstract #
10123
Poster Bd #
112
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01).
First Author: Naohito Yamamoto
Poster
2021 ASCO Annual Meeting
Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%).
First Author: Pamela N. Munster
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2023 ASCO Annual Meeting
The evolving landscape of chemotherapy for the treatment of early-stage breast cancer from 2006-2019: Results of a retrospective cohort study.
First Author: Jenna Bhimani